Vericel more than doubled its stock price on March 10 after results from a mid-stage heart failure study showed its regenerative medicine helped improve seriously ill patients.
The Cambridge, Mass.-based biotech said results of the Phase IIb ixCELL-DCM study of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM) showed fewer deaths and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?